Abbott's Xience V beats Taxus in large-scale SPIRIT IV trial
This article was originally published in Clinica
Executive Summary
Abbott's market-leading drug-eluting stent (DES) Xience V has surpassed Taxus Express2, a rival device marketed by Boston Scientific, in a clinical trial.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.